Haploid inactivation of the amplified-in-breast cancer 3 coactivator reduces the inhibitory effect of peroxisome proliferator-activated receptor γ and retinoid X receptor on cell proliferation and accelerates polyoma middle-T antigen-induced mammary tumorigenesis in mice

Cancer Research

Volumn 64, Issue 19, 2004, Pages 7169-7177

  Zhang, Hao ^a   Kuang, Shao Qing ^a   Liao, Lan ^a   Zhou, Suoling ^a   Xu, Jianming ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; HYBRID PROTEIN; NUCLEAR RECEPTOR COACTIVATOR 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYCLONAL ANTIBODY; RECOMBINANT PROTEIN; RETINOID X RECEPTOR; VIRUS MIDDLE T ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST EPITHELIUM; BREAST HYPERPLASIA; BREAST TUMOR; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; FEMALE; HAPLOIDY; IMMUNOREACTIVITY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; ONCOVIRINAE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRANSGENIC MOUSE; TUMOR VOLUME; WILD TYPE;

ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; FEMALE; HAPLOIDY; IMMUNOHISTOCHEMISTRY; LIGANDS; MALE; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; TRANSCRIPTION FACTORS;

EID: 4944228674     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1176     Document Type: Article

References (60)

1. Guan XY, Meltzer PS, Dalton WS, Trent JM. Identification of cryptic sites of DNA sequence amplification in human breast cancer by chromosome microdissection. Nat Genet 1994;8:155-61.
2. Guan XY, Xu J, Anzick SL, Zhang H, Trent JM, Meltzer PS. Hybrid selection of transcribed sequences from microdissected DNA: isolation of genes within amplified region at 20q11-q13.2 in breast cancer. Cancer Res 1996;56:3446-50.
3. Anzick SL, Kononen J, Walker RL, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science (Wash DC) 1997;277:965-8.
4. Devilee P, Schuuring E, van de Vijver MJ, Cornelisse CJ. Recent developments in the molecular genetic understanding of breast cancer [review]. Crit Rev Oncog 1994;5: 247-70.
5. Liao L, Kuang SQ, Yuan Y, Gonzalez SM, O'Malley BW, Xu J. Molecular structure and biological function of the cancer-amplified nuclear receptor coactivator SRC-3/ AIB1. J Steroid Biochem Mol Biol 2002;83:3-14.
6. Xu J, Li Q. Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol Endocrinol 2003;17:1681-92.
7. List HJ, Lauritsen KJ, Reiter R, Powers C, Wellstein A, Riegel AT. Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. J Biol Chem 2001;276:23763-8.
8. Kuang SQ, Liao L, Zhang H, Lee AV, O'Malley BW, Xu J. AIB1/SRC-3 deficiency affects insulin-like growth factor 1 signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Res 2004;64:1875-85.
9. Lee SK, Anzick SL, Choi JE, et al. A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo. J Biol Chem 1999;274:34283-93.
10. Ko L, Cardona GR, Chin WW. Thyroid hormone receptor-binding protein, an LXXLL motif-containing protein, functions as a general coactivator. Proc Natl Acad Sci USA 2000;97:6212-7.
11. Caira F, Antonson P, Pelto-Huikko M, Treuter E, Gustafsson JA. Cloning and characterization of RAP250, a novel nuclear receptor coactivator. J Biol Chem 2000;275:5308-17.
12. Zhu Y, Kan L, Qi C, et al. Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR. J Biol Chem 2000;275:13510-6.
13. Mahajan MA, Samuels HH. A new family of nuclear receptor coregulators that integrate nuclear receptor signaling through CREB-binding protein. Mol Cell Biol 2000;20:5048-63.
14. Kim SW, Park K, Kwak E, et al. Activating signal cointegrator 2 required for liver lipid metabolism mediated by liver X receptors in mice. Mol Cell Biol 2003;23:3583-92.
15. Lee SK, Na SY, Jung SY, et al. Activating protein-1, nuclear factor-kappaB, and serum response factor as novel target molecules of the cancer-amplified transcription coactivator ASC-2. Mol Endocrinol 2000;14:915-25.
16. Hong S, Lee MY, Cheong J. Functional interaction of transcriptional coactivator ASC-2 and C/EBPalpha in granulocyte differentiation of HL-60 promyelocytic cell. Biochem Biophys Res Commun 2001;282:1257-62.
17. Kong HJ, Yu HJ, Hong S, et al. Interaction and functional cooperation of the cancer-amplified transcriptional coactivator activating signal cointegrator-2 and E2F-1 in cell proliferation. Mol Cancer Res 2003;1:948-58.
18. Goo YH, Sohn YC, Kim DH, et al. Activating signal cointegrator 2 belongs to a novel steady-state complex that contains a subset of trithorax group proteins. Mol Cell Biol 2003;23:140-9.
19. Iwasaki T, Chin WW, Ko L. Identification and characterization of RRM-containing coactivator activator (CoAA) as TRBP-interacting protein, and its splice variant as a coactivator modulator (CoAM). J Biol Chem 2001;276:33375-83.
20. Auboeuf D, Honig A, Berget SM, O'Malley BW. Coordinate regulation of transcription and splicing by steroid receptor coregulators Science 2002;298:416-9.
21. Ko L, Chin WW, Nuclear receptor coactivator thyroid hormone receptor-binding protein (TRBP) interacts with and stimulates its associated DNA-dependent protein kinase. J Biol Chem 2003;278:11471-9.
22. Zhang H, Liao L, Kuang SQ, Xu J. Spatial distribution of the messenger ribonucleic acid and protein of the nuclear receptor coactivator, amplified in breast cancer-3, in mice. Endocrinology 2003;144:1435-43.
23. Kuang SQ, Liao L, Zhang H, et al. Deletion of the cancer-amplified coactivator AIB3 results in defective placentation and embryonic lethality. J Biol Chem 2002;277: 45356-60.
24. Zhu YJ, Crawford SE, Stellmach V, et al. Coactivator PRIP, the peroxisome proliferator-activated receptor-interacting protein, is a modulator of placental, cardiac, hepatic, and embryonic development. J Biol Chem 2003;278:1986-90.
25. Antonson P, Schuster GU, Wang L, et al. Inactivation of the nuclear receptor coactivator RAP250 in mice results in placental vascular dysfunction. Mol Cell Biol 2003;23:1260-8.
26. Barak Y, Nelson MC, Ong ES, et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999;4:585-95.
27. Zhu Y, Qi C, Jia Y, Nye JS, Rao MS, Reddy JK. Deletion of PBP/PPARBP, the gene for nuclear receptor coactivator peroxisome proliferator-activated receptor-binding protein, results in embryonic lethality. J Biol Chem 2000;275:14779-82.
28. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992;12:954-61.
29. Courtneidge SA, Heber A. An 81 kD protein complexed with middle T antigen and pp60c-src: a possible phosphatidylinositol kinase. Cell 1987;50:1031-7.
30. Courtneidge SA, Smith AE. The complex of polyoma virus middle-T antigen and pp60c-src. EMBO J 1984;3:585-91.
31. Dilworth SM, Brewster CE, Jones MD, Lanfrancone L, Pelicci G, Pelicci PG. Transformation by polyoma virus middle T-antigen involves the binding and tyrosine phosphorylation of Shc. Nature (Lond) 1994;367:87-90.
32. Maglione JE, Moghanaki D, Young LJ, et al. Transgenic polyoma middle-T mice model premalignant mammary disease. Cancer Res 2001;61:8298-305.
33. Lin EY, Jones JG, Li P, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 2003;163:2113-26.
34. Neznanov N, Man AK, Yamamoto H, Hauser CA, Cardiff RD, Oshima RG. A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice. Cancer Res 1999;59:4242-6.
35. Xu J, Nakahara M, Crabb JW, et al. Expression and immunochemical analysis of rat and human fibroblast growth factor receptor (flg) isoforms. J Biol Chem 1992;267: 17792-803.
36. Xu J, Qiu Y, DeMayo FJ, Tsai SY, Tsai MJ, O'Malley BW. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene Science (Wash DC) 1998;279:1922-5.
37. Yuan Y, Liao L, Tulis DA, Xu J. Steroid receptor coactivator-3 is required for inhibition of neointima formation by estrogen. Circulation 2002;105:2653-9.
38. Seth P, Porter D, Lahti-Domenici J, Geng Y, Richardson A, Polyak K. Cellular and molecular targets of estrogen in normal human breast tissue. Cancer Res 2002;62: 4540-4.
39. Sacco MG, Gribaldo L, Barbieri O, et al. Establishment and characterization of a new mammary adenocarcinoma cell line derived from MMTV neu transgenic mice. Breast Cancer Res Treat 1998;47:171-80.
40. Ajiro K, Yoda K, Utsumi K, Nishikawa Y. Alteration of cell cycle-dependent histone phosphorylations by okadaic acid. Induction of mitosis-specific H3 phosphorylation and chromatin condensation in mammalian interphase cells. J Biol Chem 1996;271: 13197-201.
41. Harvell DM, Strecker TE, Tochacek M, et al. Rat strain-specific actions of 17beta-estradiol in the mammary gland: correlation between estrogen-induced lobuloalveolar hyperplasia and susceptibility to estrogen-induced mammary cancers. Proc Natl Acad Sci USA 2000;97:2779-84.
42. Fendrick JL, Raafat AM, Haslam SZ. Mammary gland growth and development from the postnatal period to postmenopause: ovarian steroid receptor ontogeny and regulation in the mouse. J Mammary gland Biol Neoplasia 1998;3:7-22.
43. Mueller E, Sarraf P, Tontonoz P, et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998;1:465-70.
44. Mehta RG, Williamson E, Patel MK, Koeffler HP. A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst (Bethesda) 2000;92:418-23.
45. Pighetti GM, Novosad W, Nicholson C, et al. Therapeutic treatment of DMBA-induced mammary tumors with PPAR ligands. Anticancer Res 2001;21:825-9.
46. Wu K, Zhang Y, Xu XC, et al. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res 2002;62:6376-80.
47. Wu K, Kim HT, Rodriquez JL, et al. 9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice. Clin Cancer Res 2000;6:3696-704.
48. Gimun GD, Smith WM, Drori S, et al. APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci USA 2002;99:13771-6.
49. Osawa E, Nakajima A, Wada K, et al. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 2003;124:361-7.
50. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001;193:727-40.
51. Saez E, Rosenfeld J, Livolsi A, et al. PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev 2004;18:528-40.
52. Martin G, Davio C, Rivera E, et al. Hormone dependence of mammary tumors induced in rats by intraperitoneal NMU injection. Cancer Investig 1997;15:8-17.
53. Fishman J, Osborne MP, Telang NT. The role of estrogen in mammary carcinogenesis. Ann NY Acad Sci 1995;768:91-100.
54. Bocchinfuso WP, Hively WP, Couse JF, Varmus HE, Korach KS. A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha. Cancer Res 1999;59:1869-76.
55. Han C, Demetris AJ, Michalopoulos GK, Zhan Q, Shelhamer JH, Wu T. PPAR-gamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway. Hepatology 2003;38:167-77.
56. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998;4:1046-52.
57. Yang LM, Tin UC, Wu K, Brown P. Role of retinoid receptors in the prevention and treatment of breast cancer. J Mammary gland Biol Neopiasia 1999;4:377-88.
58. Dilworth SM. Polyoma virus middle T antigen and its role in identifying cancer-related molecules. Nat Rev Cancer 2002;2:951-6.
59. Hu E, Kim JB, Sarraf P, Spiegelman BM. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science (Wash DC) 1996;274: 2100-3.
60. Adams M, Reginato MJ, Shao D, Lazar MA, Chatterjee VK. Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem 1997;272: 5128-32.